These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR; J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 infection and cognitive impairment in the cART era: a review. Schouten J; Cinque P; Gisslen M; Reiss P; Portegies P AIDS; 2011 Mar; 25(5):561-75. PubMed ID: 21160410 [TBL] [Abstract][Full Text] [Related]
8. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. Bakanda C; Birungi J; Mwesigwa R; Ford N; Cooper CL; Au-Yeung C; Chan K; Nachega JB; Wood E; Hogg RS; Dybul M; Mills EJ AIDS; 2011 Mar; 25(5):701-5. PubMed ID: 21160412 [TBL] [Abstract][Full Text] [Related]
9. No change to HIV-1 latency with valproate therapy. Steel A; Clark S; Teo I; Shaunak S; Nelson M; Gazzard B; Kelleher P AIDS; 2006 Aug; 20(12):1681-2. PubMed ID: 16868456 [No Abstract] [Full Text] [Related]
10. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516 [TBL] [Abstract][Full Text] [Related]
11. Reduction of glutamate levels in HIV-infected subjects treated with acetylcarnitine. Famularo G; Moretti S; Alesse E; Trinchieri V; Angelucci A; Santini G; Cifone G; De Simone C J NeuroAIDS; 1999; 2(2):65-73. PubMed ID: 16873195 [TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825 [TBL] [Abstract][Full Text] [Related]
13. Dementia and neurocognitive disorders due to HIV-1 infection. Ances BM; Ellis RJ Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745 [TBL] [Abstract][Full Text] [Related]
14. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Sagot-Lerolle N; Lamine A; Chaix ML; Boufassa F; Aboulker JP; Costagliola D; Goujard C; Pallier C; Delfraissy JF; Lambotte O; AIDS; 2008 Jun; 22(10):1125-9. PubMed ID: 18525257 [TBL] [Abstract][Full Text] [Related]
15. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). Wagner GJ; Kanouse DE; Golinelli D; Miller LG; Daar ES; Witt MD; Diamond C; Tilles JG; Kemper CA; Larsen R; Goicoechea M; Haubrich RH AIDS; 2006 Jun; 20(9):1295-302. PubMed ID: 16816559 [TBL] [Abstract][Full Text] [Related]
16. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. Fox J; Dustan S; McClure M; Weber J; Fidler S HIV Med; 2006 Oct; 7(7):477-83. PubMed ID: 16925735 [TBL] [Abstract][Full Text] [Related]
17. Study on CD4 cell responses in HIV infected subjects in Nepal. Tiwari BR; Ghimire P; Malla S Nepal Med Coll J; 2008 Mar; 10(1):45-7. PubMed ID: 18700632 [TBL] [Abstract][Full Text] [Related]
19. Anti-HIV agents. Can valproic acid help flush HIV from hiding? TreatmentUpdate; 2005; 17(6):4-5. PubMed ID: 17228475 [No Abstract] [Full Text] [Related]
20. Effect of HIV viral load, CD4 cell count and antiretroviral therapy on human papillomavirus prevalence in urine samples of HIV-infected men. Jong E; van Gorp EC; Mulder JW; Tol A; Smits PH Int J STD AIDS; 2009 Apr; 20(4):262-4. PubMed ID: 19304972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]